All about blinatumomab: the bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia.

MLA

Mirfakhraie, Reza, et al. “All about Blinatumomab: The Bispecific T Cell Engager Immunotherapy for B Cell Acute Lymphoblastic Leukemia.” Hematology, Transfusion and Cell Therapy, vol. 46, no. 2, Apr. 2024, pp. 192–200. EBSCOhost, https://doi.org/10.1016/j.htct.2023.06.006.

APA

Mirfakhraie, R., Dehaghi, B. K., Ghorbi, M. D., Ghaffari-Nazari, H., Mohammadian, M., Salimi, M., Ardakani, M. T., & Parkhideh, S. (2024). All about blinatumomab: the bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia. Hematology, Transfusion and Cell Therapy, 46(2), 192–200. https://doi.org/10.1016/j.htct.2023.06.006

Chicago

Mirfakhraie, Reza, Bentolhoda Kuhestani Dehaghi, Mahmoud Dehghani Ghorbi, Haniyeh Ghaffari-Nazari, Mozhdeh Mohammadian, Maryam Salimi, Maria Tavakoli Ardakani, and Sayeh Parkhideh. 2024. “All about Blinatumomab: The Bispecific T Cell Engager Immunotherapy for B Cell Acute Lymphoblastic Leukemia.” Hematology, Transfusion and Cell Therapy 46 (2): 192–200. doi:10.1016/j.htct.2023.06.006.